According to the lawsuit, throughout the Class Period, defendants made made false and/or misleading statements and/or failed to disclose that:
- Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates;
- SC291 in oncology, SC379, and SG299 were less promising than defendants had led investors to believe;
- in order to preserve cash and advance its more promising product candidates, Sana was likely to decrease funding for and/or discontinue SC291 in oncology, SC379, and SG299, as well as significantly reduce its headcount;
- accordingly, defendants overstated Sana’s financial capacity to maintain its current operations and advance its existing product candidates; and
- as a result, defendants’ public statements were materially false and/or misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
